Med. praxi. 2015;12(1):27-29

Vaccination against meningococcal disease

MUDr.Pavla Křížová, CSc.
Národní referenční laboratoř pro meningokokové nákazy, Státní zdravotní ústav, Praha

Despite the advances in medicine, invasive meningococcal disease is still one of the most deadly infectious diseases. In most European

countries, vaccination against this disease is recommended. Although no vaccine universally effective against all meningococcal serogroups

is currently available, protection against most meningococcal serogroups can be achieved by combining two available vaccines: MenB

vaccine and tetravalent A, C, Y, and W135 conjugate vaccine. The national immunization committees in various countries update the vaccination

guidelines, taking into account the epidemiological situation and development and availability of novel meningococcal vaccines.

Keywords: invasive meningococcal disease, meningococcal vaccine, vaccination strategy

Published: February 27, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Křížová P. Vaccination against meningococcal disease. Med. praxi. 2015;12(1):27-29.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Křížová P, Rožnovský L. Meningokokové onemocnění. Praha: MAXDORF, 2011: 272.
    2. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001; 19(17-19): 2688-2691. Go to original source... Go to PubMed...
    3. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluace the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010; 107(45): 19490-19495. Go to original source... Go to PubMed...
    4. Vogel U, Taha MK, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis, 2013; 13(5): 416-425. Go to original source... Go to PubMed...
    5. Křížová P, Musílek M, Vacková Z, Kozáková J, Claus H, Vogel U, Medini D. Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic. Epidemiologie, mikrobiologie, imunologie 2014; 63(2): 103-106.
    6. Frosi G, Biolchi A, Lo Sapio M, et al. Bactericidal antipody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013; 31(43): 4968-4974. Go to original source... Go to PubMed...
    7. Křížová P, Vacková Z, Musílek M, Kozáková J. Invazivní meningokokové onemocnění v České republice - surveillance a doporučení k vakcinační strategii. Epidemiologie, mikrobiologie, imunologie 2013; 62(4): 138-147.
    8. Křížová P, Musílek M, Vacková Z, Bečvářová Z, Kozáková J. Sekvenční analýza antigenů zařazených v čtyřkomponentní vakcíně proti meningokoky B v českých izolátech Neisseria meningitidis v období 2007-2013. Epidemiologie, mikrobiologie, imunologie 2014; 63(1): 61-68.
    9. Křížová P. Invazivní meningokokové onemocnění - aktuální epidemiologická situace a možnosti očkování proti meningokokům. Vakcinologie 2014; 8(1): 6-10.
    10. Andrew L, Kwok-Leung L, Murphy E, et al. Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup B Neisseria Meningitidis. The Journal of Infectious Diseases 2009; 200: 379-389. Go to original source... Go to PubMed...
    11. Hubert K, Devos N, Mordhorst I, et al. ZnuD a Potential Candidate for a Simple and Universal Neisseria meningitidis Vaccine. Infection and Immunity 2013; 81(6): 1915-1927. Go to original source... Go to PubMed...
    12. Bambini S, Muzzi A, Olcen P, et al. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009; 27: 2794-2803. Go to original source... Go to PubMed...
    13. Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine, 2012; 30(Suppl 2): B26-36. Go to original source... Go to PubMed...
    14. Kriz P, Wieffer H, Holl K, et al. Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century. Expert Review of Vaccines, 2011; 10: 1477-1486. Go to original source... Go to PubMed...
    15. Jacobson RM, Jackson LA, Reisinger K, et al. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J, 2013; 32, doi: 10.1097/INF.0b013e318279ac38. Go to original source... Go to PubMed...
    16. Khatami A, Snape MD, Davis E, et al. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine, 2012; 30: 2831-2838. Go to original source... Go to PubMed...
    17. Broker M, Jacobsson S, Kuusi M, et al. Meningococcal serogroup Y emergence in Europe: Update 2011. Hum Vaccin Immunother, 2012; (12). [Epub ahead of print] Go to original source... Go to PubMed...
    18. Esposito S, Prymula R, Vesikari T, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013; 381: 825-835. Go to original source... Go to PubMed...
    19. Ramsay ME, Andrews N, Kaczmarski EB, et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toodlers in England. Lancet, 2001; 357(9251): 195-196. Go to original source... Go to PubMed...
    20. Trotter CL, Andrews NJ, Kaczmarski EB, et al., Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet, 2004; 364(9431): 365-367. Go to original source... Go to PubMed...
    21. Campbell H, Andrews N, Borrow R, et al. Updated postlicencure surveillance of the meningococcal connugate vaccine in England and Wales: effectiveness, validation of serological corelates of protection, and modeling predictions of the duration of herd imunity. Clin Vaccine Immunol, 2010; 17(5): 840-847. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.